Ryan & Maniskas, LLP Announces Investigation of Chelsea Therapeutics
WAYNE, Pa., May 9, 2014
WAYNE, Pa., May 9, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating
potential claims against the board of directors of Chelsea Therapeutics
International Ltd. ("Chelsea Therapeutics" or the "Company") (NASDAQ: CHTP)
concerning possible breaches of fiduciary duty and other violations of law
related to the Company's efforts to sell the Company to H. Lundbeck A/S in a
transaction valued at approximately $658 million.
Ryan & Maniskas, LLP.
If you own shares of Chelsea Therapeutics and would like to learn more about
this class action or if you wish to discuss these matters and have any
questions concerning this announcement or your rights, contact Richard A.
Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit:
www.rmclasslaw.com/cases/chtp. You may also email Mr. Maniskas at
Under the terms of the agreement, shareholders of Chelsea Therapeutics would
receive $6.44 in cash, and up to $1.50 per share in a Contingent Value Right,
for each share of Chelsea Therapeutics they own.
Our investigation concerns possible breaches of fiduciary duty and other
violations of state law by the Board of Directors of Chelsea Therapeutics for
not acting in the Company's shareholders' best interests in connection with
the sale process.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan &
Maniskas, LLP is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal courts
nationwide. To learn more about the class action process, please visit:
CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
SOURCE Ryan & Maniskas, LLP
Press spacebar to pause and continue. Press esc to stop.